PIO Laser Sclerectomy IOP SLT Sclerectomy
- Conditions
- Primary Open-Angle Glaucoma
- Interventions
- Procedure: Selective Laser Trabeculoplasty (Tango Laser, Ellex)
- Registration Number
- NCT01798732
- Lead Sponsor
- University Hospital, Grenoble
- Brief Summary
The main objective of this study is to characterize the changes in IOP over 24 hours after selective trabeculoplasty SLT (before and 1 and 6 months after treatment, decreased IOP, type of rhythm, mesor, acrophase, amplitude). The secondary objective is to evaluate changes in ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after selective laser trabeculoplasty.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
- Primary Open-Angle Glaucoma
- IOP more than 21 mmHg
- Progression under maximal medical therapy
- aged more than 18 years
- Pregnant woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Selective laser trabeculoplasty (Tango Laser, Ellex) Selective Laser Trabeculoplasty (Tango Laser, Ellex) Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
- Primary Outcome Measures
Name Time Method IOP change over 24 hours after selective trabeculoplasty SLT according to chronobiological data (decrease of IOP; type of 24h-IOP rhythm and 24h-PPm rhythm: MESOR, acrophase, bathyphase, amplitude and modeling) Baseline and 6 months
- Secondary Outcome Measures
Name Time Method Changes in the rate of ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after SLT. Baseline and 6 months * To find predictive factors 1 month before efficacy of the treatment (after 6 month). Efficacy is defined by a mean IOP decrease, at least 30%, with a smoothed pressure-peaks (decrease at least 40% of pressure changes)
* To characterize changes of ocular blood flow parameters (optic nerve head; Volume, Velocity and Flow): 20% at least of increase.
Trial Locations
- Locations (1)
University Hospital of Grenoble
🇫🇷Grenoble, France